

Bernd Schnabl

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5402112/bernd-schnabl-publications-by-year.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

125 papers	8,503 citations	44 h-index	91 g-index
145 ext. papers	11,577 ext. citations	9 avg, IF	6.62 L-index

#	Paper	IF	Citations
125	Colesevelam ameliorates non-alcoholic steatohepatitis and obesity in mice.. <i>Hepatology International</i> , 2022 , 1	8.8	2
124	Liver specific, systemic and genetic contributors to alcohol-related liver disease progression.. <i>Zeitschrift Fur Gastroenterologie</i> , 2022 , 60, 36-44	1.6	0
123	ROR β phosphorylation protects against T β cell-mediated inflammation.. <i>Cell Reports</i> , 2022 , 38, 110520	10.6	2
122	Effect of rifaximin on infections, acute-on-chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFA-AH).. <i>Liver International</i> , 2022 ,	7.9	1
121	Lipidomics for the Prediction of Progressive Liver Disease in Patients with Alcohol Use Disorder. <i>Metabolites</i> , 2022 , 12, 433	5.6	1
120	Promises of microbiome-based therapies.. <i>Journal of Hepatology</i> , 2022 , 76, 1379-1391	13.4	2
119	Update on the Role of the Gut Microbiota on Alcohol-Associated Liver Disease. <i>Gastroenterology and Hepatology</i> , 2021 , 17, 381-383	0.7	
118	Host Factors in Dysregulation of the Gut Barrier Function during Alcohol-Associated Liver Disease. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	1
117	Bacteriophages and their potential for treatment of gastrointestinal diseases. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021 ,	24.2	1
116	Gut dysbiosis as a driver in alcohol-induced liver injury. <i>JHEP Reports</i> , 2021 , 3, 100220	10.3	12
115	An Introduction to Next Generation Sequencing Bioinformatic Analysis in Gut Microbiome Studies. <i>Biomolecules</i> , 2021 , 11,	5.9	11
114	A semiparametric model for between-subject attributes: Applications to beta-diversity of microbiome data. <i>Biometrics</i> , 2021 ,	1.8	1
113	Combined analysis of gut microbiota, diet and PNPLA3 polymorphism in biopsy-proven non-alcoholic fatty liver disease. <i>Liver International</i> , 2021 , 41, 1576-1591	7.9	2
112	Colesevelam Reduces Ethanol-Induced Liver Steatosis in Humanized Gnotobiotic Mice. <i>Cells</i> , 2021 , 10,	7.9	1
111	The microbiota in cirrhosis and its role in hepatic decompensation. <i>Journal of Hepatology</i> , 2021 , 75 Suppl 1, S67-S81	13.4	23
110	The selective PPAR-delta agonist seladelpar reduces ethanol-induced liver disease by restoring gut barrier function and bile acid homeostasis in mice. <i>Translational Research</i> , 2021 , 227, 1-14	11	6
109	Microbial Products and Metabolites Contributing to Alcohol-Related Liver Disease. <i>Molecular Nutrition and Food Research</i> , 2021 , 65, e2000023	5.9	5

108	The gut mycobiome: a novel player in chronic liver diseases. <i>Journal of Gastroenterology</i> , 2021 , 56, 1-11	6.9	9
107	Targeting pathobionts for the treatment of alcohol-associated liver disease. <i>Liver International</i> , 2021 , 41, 239-240	7.9	1
106	Targeting the gut-liver-immune axis to treat cirrhosis. <i>Gut</i> , 2021 , 70, 982-994	19.2	23
105	Current Concepts, Opportunities, and Challenges of Gut Microbiome-Based Personalized Medicine in Nonalcoholic Fatty Liver Disease. <i>Cell Metabolism</i> , 2021 , 33, 21-32	24.6	37
104	Gut microbiome, liver immunology, and liver diseases. <i>Cellular and Molecular Immunology</i> , 2021 , 18, 4-17	15.4	45
103	Gut Microbiome Directs Hepatocytes to Recruit MDSCs and Promote Cholangiocarcinoma. <i>Cancer Discovery</i> , 2021 , 11, 1248-1267	24.4	29
102	Microbiome of the Aerodigestive Tract in Health and Esophageal Disease. <i>Digestive Diseases and Sciences</i> , 2021 , 66, 12-18	4	3
101	Nonalcoholic Steatohepatitis and HCC in a Hyperphagic Mouse Accelerated by Western Diet. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021 , 12, 891-920	7.9	1
100	New Developments in Microbiome in Alcohol-Associated and Nonalcoholic Fatty Liver Disease. <i>Seminars in Liver Disease</i> , 2021 , 41, 87-102	7.3	0
99	Serum Acylcarnitines Associated with High Short-Term Mortality in Patients with Alcoholic Hepatitis. <i>Biomolecules</i> , 2021 , 11,	5.9	2
98	Fungi-Bacteria Correlation in Alcoholic Hepatitis Patients. <i>Toxins</i> , 2021 , 13,	4.9	3
97	Dynamic Changes of the Fungal Microbiome in Alcohol Use Disorder. <i>Frontiers in Physiology</i> , 2021 , 12, 699253	4.6	6
96	Intestinal virome and therapeutic potential of bacteriophages in liver disease. <i>Journal of Hepatology</i> , 2021 , 75, 1465-1475	13.4	7
95	Aryl Hydrocarbon Receptor Deficiency in Intestinal Epithelial Cells Aggravates Alcohol-Related Liver Disease. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021 , 13, 233-256	7.9	2
94	Trajectory of Serum Bilirubin Predicts Spontaneous Recovery in a Real-World Cohort of Patients With Alcoholic Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	3
93	Intestinal α -2-Fucosylation Contributes to Obesity and Steatohepatitis in Mice. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021 , 12, 293-320	7.9	2
92	CRlg on liver macrophages clears pathobionts and protects against alcoholic liver disease. <i>Nature Communications</i> , 2021 , 12, 7172	17.4	3
91	Functional Microbial Responses to Alcohol Abstinence in Patients With Alcohol Use Disorder. <i>Frontiers in Physiology</i> , 2020 , 11, 370	4.6	5

90	Gut Microbiota in Liver Disease: What Do We Know and What Do We Not Know?. <i>Physiology</i> , 2020 , 35, 261-274	9.8	14
89	Alcoholic-Hepatitis, Links to Brain and Microbiome: Mechanisms, Clinical and Experimental Research. <i>Biomedicines</i> , 2020 , 8,	4.8	6
88	Differential Activation of Unconventional T Cells, Including iNKT Cells, in Alcohol-Related Liver Disease. <i>Alcoholism: Clinical and Experimental Research</i> , 2020 , 44, 1061-1074	3.7	4
87	Intestinal Virome Signature Associated With Severity of Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2020 , 159, 1839-1852	13.3	37
86	Intestinal permeability, microbial translocation, changes in duodenal and fecal microbiota, and their associations with alcoholic liver disease progression in humans. <i>Gut Microbes</i> , 2020 , 12, 1782157	8.8	32
85	Deficiency of Intestinal α -2-Fucosylation Exacerbates Ethanol-Induced Liver Disease in Mice. <i>Alcoholism: Clinical and Experimental Research</i> , 2020 , 44, 1842-1851	3.7	5
84	Intestinal Virome in Patients With Alcoholic Hepatitis. <i>Hepatology</i> , 2020 , 72, 2182-2196	11.2	29
83	Cytolysin-positive <i>Enterococcus faecalis</i> is not increased in patients with non-alcoholic steatohepatitis. <i>Liver International</i> , 2020 , 40, 860-865	7.9	18
82	From intestinal dysbiosis to alcohol-associated liver disease. <i>Clinical and Molecular Hepatology</i> , 2020 , 26, 595-605	6.9	11
81	Tumor necrosis factor alpha receptor 1 deficiency in hepatocytes does not protect from non-alcoholic steatohepatitis, but attenuates insulin resistance in mice. <i>World Journal of Gastroenterology</i> , 2020 , 26, 4933-4944	5.6	2
80	A Novel Mouse Model of Acute-on-Chronic Cholestatic Alcoholic Liver Disease: A Systems Biology Comparison With Human Alcoholic Hepatitis. <i>Alcoholism: Clinical and Experimental Research</i> , 2020 , 44, 87-101	3.7	1
79	Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting. <i>Gut</i> , 2020 , 69, 764-780	19.2	39
78	Changes in the fecal bacterial microbiota associated with disease severity in alcoholic hepatitis patients. <i>Gut Microbes</i> , 2020 , 12, 1785251	8.8	23
77	Transcriptomic Profiling Identifies Novel Hepatic and Intestinal Genes Following Chronic Plus Binge Ethanol Feeding in Mice. <i>Digestive Diseases and Sciences</i> , 2020 , 65, 3592-3604	4	6
76	Persistent SARS-CoV-2 RNA Positive in Feces but Negative in Breastmilk: A Case Report of COVID-19 in a Breastfeeding Patient. <i>Frontiers in Medicine</i> , 2020 , 7, 562700	4.9	6
75	Functional Microbiomics Reveals Alterations of the Gut Microbiome and Host Co-Metabolism in Patients With Alcoholic Hepatitis. <i>Hepatology Communications</i> , 2020 , 4, 1168-1182	6	8
74	Microbiota and Fatty Liver Disease-the Known, the Unknown, and the Future. <i>Cell Host and Microbe</i> , 2020 , 28, 233-244	23.4	46
73	Multicenter Analysis of Liver Injury Patterns and Mortality in COVID-19. <i>Frontiers in Medicine</i> , 2020 , 7, 584342	4.9	10

72	Skin wound closure delay in metabolic syndrome correlates with SCF deficiency in keratinocytes. <i>Scientific Reports</i> , 2020 , 10, 21732	4.9	1
71	Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients With Alcoholic Hepatitis. <i>Hepatology</i> , 2020 , 71, 522-538	11.2	71
70	Intestinal and hepatic microbiota changes associated with chronic ethanol administration in mice. <i>Gut Microbes</i> , 2020 , 11, 265-275	8.8	22
69	The Candida albicans exotoxin candidalysin promotes alcohol-associated liver disease. <i>Journal of Hepatology</i> , 2020 , 72, 391-400	13.4	41
68	High Protein Intake Is Associated With Histological Disease Activity in Patients With NAFLD. <i>Hepatology Communications</i> , 2020 , 4, 681-695	6	16
67	Serum and Fecal Oxylipins in Patients with Alcohol-Related Liver Disease. <i>Digestive Diseases and Sciences</i> , 2019 , 64, 1878-1892	4	16
66	Intestinal iNKT cells migrate to liver and contribute to hepatocyte apoptosis during alcoholic liver disease. <i>American Journal of Physiology - Renal Physiology</i> , 2019 , 316, G585-G597	5.1	14
65	Indoles: metabolites produced by intestinal bacteria capable of controlling liver disease manifestation. <i>Journal of Internal Medicine</i> , 2019 , 286, 32-40	10.8	53
64	Gut microbiota in liver disease: too much is harmful, nothing at all is not helpful either. <i>American Journal of Physiology - Renal Physiology</i> , 2019 , 316, G563-G573	5.1	32
63	Role of the intestinal microbiome in liver fibrosis development and new treatment strategies. <i>Translational Research</i> , 2019 , 209, 22-38	11	18
62	YIPF6 controls sorting of FGF21 into COPII vesicles and promotes obesity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 15184-15193	11.5	10
61	Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. <i>Nature</i> , 2019 , 575, 505-511	50.4	245
60	Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease. <i>Gut</i> , 2019 , 68, 359-370	19.2	142
59	Antimicrobial proteins: intestinal guards to protect against liver disease. <i>Journal of Gastroenterology</i> , 2019 , 54, 209-217	6.9	21
58	Bacteria engineered to produce IL-22 in intestine induce expression of REG3G to reduce ethanol-induced liver disease in mice. <i>Gut</i> , 2019 , 68, 1504-1515	19.2	100
57	Microbiome 101: Studying, Analyzing, and Interpreting Gut Microbiome Data for Clinicians. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 218-230	6.9	107
56	Microbiome as a therapeutic target in alcohol-related liver disease. <i>Journal of Hepatology</i> , 2019 , 70, 260-274	27.4	105
55	Intestinal Microbiota Mediates the Susceptibility to Polymicrobial Sepsis-Induced Liver Injury by Granisetron Generation in Mice. <i>Hepatology</i> , 2019 , 69, 1751-1767	11.2	48

54	Gut microbiota, fatty liver disease, and hepatocellular carcinoma. <i>Liver Research</i> , 2018 , 2, 43-51	4.1	44
53	Gut microbiota mediates diurnal variation of acetaminophen induced acute liver injury in mice. <i>Journal of Hepatology</i> , 2018 , 69, 51-59	13.4	89
52	Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis. <i>Journal of Hepatology</i> , 2018 , 69, 396-405	13.4	83
51	Risk factors for progression of and treatment options for NAFLD in children. <i>Clinical Liver Disease</i> , 2018 , 11, 11-15	2.2	11
50	Digoxin Suppresses Pyruvate Kinase M2-Promoted HIF-1 α Transactivation in Steatohepatitis. <i>Cell Metabolism</i> , 2018 , 27, 339-350.e3	24.6	34
49	Intestinal dysbiosis and permeability: the yin and yang in alcohol dependence and alcoholic liver disease. <i>Clinical Science</i> , 2018 , 132, 199-212	6.5	47
48	β -Hydroxybutyrate protects from alcohol-induced liver injury via a Hcar2-cAMP dependent pathway. <i>Journal of Hepatology</i> , 2018 , 69, 687-696	13.4	25
47	Immunoglobulin A and liver diseases. <i>Journal of Gastroenterology</i> , 2018 , 53, 691-700	6.9	18
46	New mitochondrial DNA synthesis enables NLRP3 inflammasome activation. <i>Nature</i> , 2018 , 560, 198-203	50.4	394
45	The gut-liver axis and the intersection with the microbiome. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018 , 15, 397-411	24.2	465
44	Pyroptosis by caspase11/4-gasdermin-D pathway in alcoholic hepatitis in mice and patients. <i>Hepatology</i> , 2018 , 67, 1737-1753	11.2	103
43	Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with non-alcoholic fatty liver disease. <i>British Journal of Pharmacology</i> , 2018 , 175, 469-484	8.6	53
42	Modulation of the intestinal bile acid/farnesoid X receptor/fibroblast growth factor 15 axis improves alcoholic liver disease in mice. <i>Hepatology</i> , 2018 , 67, 2150-2166	11.2	118
41	Reply to: "Finding fibroblast growth factor 19 during cholestasis: Does x mark the spot?". <i>Journal of Hepatology</i> , 2018 , 69, 1400-1401	13.4	
40	Complex Network of NKT Cell Subsets Controls Immune Homeostasis in Liver and Gut. <i>Frontiers in Immunology</i> , 2018 , 9, 2082	8.4	22
39	Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. <i>Cell Metabolism</i> , 2017 , 25, 1054-1062.e5	24.6	457
38	Gastric acid suppression promotes alcoholic liver disease by inducing overgrowth of intestinal Enterococcus. <i>Nature Communications</i> , 2017 , 8, 837	17.4	118
37	Weight Loss Decreases Magnetic Resonance Elastography Estimated Liver Stiffness in Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 463-464	6.9	24

36	Extracellular vesicles released by hepatocytes from gastric infusion model of alcoholic liver disease contain a MicroRNA barcode that can be detected in blood. <i>Hepatology</i> , 2017 , 65, 475-490	11.2	64
35	Intestinal fungi contribute to development of alcoholic liver disease. <i>Journal of Clinical Investigation</i> , 2017 , 127, 2829-2841	15.9	209
34	Fast-Track Clearance of Bacteria from the Liver. <i>Cell Host and Microbe</i> , 2016 , 20, 1-2	23.4	32
33	Acute-on-chronic liver failure in cirrhosis. <i>Nature Reviews Disease Primers</i> , 2016 , 2, 16041	51.1	205
32	Genetic Loss of Immunoglobulin A Does Not Influence Development of Alcoholic Steatohepatitis in Mice. <i>Alcoholism: Clinical and Experimental Research</i> , 2016 , 40, 2604-2613	3.7	16
31	Staging of fibrosis in experimental non-alcoholic steatohepatitis by quantitative molecular imaging in rat models. <i>Nuclear Medicine and Biology</i> , 2016 , 43, 179-87	2.1	5
30	Intestinal REG3 Lectins Protect against Alcoholic Steatohepatitis by Reducing Mucosa-Associated Microbiota and Preventing Bacterial Translocation. <i>Cell Host and Microbe</i> , 2016 , 19, 227-39	23.4	197
29	Liver capsule: Mechanisms of alcoholic hepatitis. <i>Hepatology</i> , 2016 , 64, 276	11.2	5
28	Does the Intestinal Microbiota Explain Differences in the Epidemiology of Liver Disease between East and West?. <i>Inflammatory Intestinal Diseases</i> , 2016 , 1, 3-8	2.5	3
27	Bidirectional Communication between Liver and Gut during Alcoholic Liver Disease. <i>Seminars in Liver Disease</i> , 2016 , 36, 331-339	7.3	57
26	Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota. <i>American Journal of Physiology - Renal Physiology</i> , 2016 , 311, G1018-G1036	5.1	49
25	Deficiency of intestinal mucin-2 protects mice from diet-induced fatty liver disease and obesity. <i>American Journal of Physiology - Renal Physiology</i> , 2016 , 310, G310-22	5.1	29
24	Microbiota and Alcoholic Liver Disease. <i>Alcoholism: Clinical and Experimental Research</i> , 2016 , 40, 1791-2	3.7	8
23	Is intestinal inflammation linking dysbiosis to gut barrier dysfunction during liver disease?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015 , 9, 1069-76	4.2	39
22	Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis. <i>Journal of Hepatology</i> , 2015 , 63, 1272-84	13.4	323
21	Commensal microbiota is hepatoprotective and prevents liver fibrosis in mice. <i>FASEB Journal</i> , 2015 , 29, 1043-55	0.9	117
20	Supplementation of saturated long-chain fatty acids maintains intestinal eubiosis and reduces ethanol-induced liver injury in mice. <i>Gastroenterology</i> , 2015 , 148, 203-214.e16	13.3	193
19	Microbiota Protects Mice Against Acute Alcohol-Induced Liver Injury. <i>Alcoholism: Clinical and Experimental Research</i> , 2015 , 39, 2313-23	3.7	71

18	The gut microbiota and liver disease. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2015 , 1, 275-284	7.9	104
17	Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. <i>Nature Medicine</i> , 2015 , 21, 159-65	50.5	420
16	Effect of weight loss on magnetic resonance imaging estimation of liver fat and volume in patients with nonalcoholic steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 561-568.e1	6.9	91
15	Methods to determine intestinal permeability and bacterial translocation during liver disease. <i>Journal of Immunological Methods</i> , 2015 , 421, 44-53	2.5	142
14	Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. <i>Journal of Hepatology</i> , 2014 , 60, 1310-24	13.4	535
13	Interactions between the intestinal microbiome and liver diseases. <i>Gastroenterology</i> , 2014 , 146, 1513-24	13.3	596
12	Nod2 deficiency protects mice from cholestatic liver disease by increasing renal excretion of bile acids. <i>Journal of Hepatology</i> , 2014 , 60, 1259-67	13.4	18
11	Host-microbiome interactions in alcoholic liver disease. <i>Gut and Liver</i> , 2014 , 8, 237-41	4.8	58
10	Insulin Resistance Increases MRI-Estimated Pancreatic Fat in Nonalcoholic Fatty Liver Disease and Normal Controls. <i>Gastroenterology Research and Practice</i> , 2013 , 2013, 498296	2	32
9	Fibroblast growth factor inducible 14 as potential target in patients with alcoholic hepatitis. <i>Gut</i> , 2013 , 62, 335-6	19.2	
8	Linking intestinal homeostasis and liver disease. <i>Current Opinion in Gastroenterology</i> , 2013 , 29, 264-70	3	52
7	Deficiency of intestinal mucin-2 ameliorates experimental alcoholic liver disease in mice. <i>Hepatology</i> , 2013 , 58, 108-19	11.2	147
6	Origin of myofibroblasts in liver fibrosis. <i>Fibrogenesis and Tissue Repair</i> , 2012 , 5, S17		79
5	Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease. <i>Journal of Hepatology</i> , 2012 , 56, 1283-92	13.4	219
4	Toll-like receptor 2-mediated intestinal injury and enteric tumor necrosis factor receptor I contribute to liver fibrosis in mice. <i>Gastroenterology</i> , 2012 , 143, 1330-1340.e1	13.3	85
3	Enteric dysbiosis associated with a mouse model of alcoholic liver disease. <i>Hepatology</i> , 2011 , 53, 96-105	11.2	494
2	A TLR4/MD2 fusion protein inhibits LPS-induced pro-inflammatory signaling in hepatic stellate cells. <i>Biochemical and Biophysical Research Communications</i> , 2008 , 375, 210-4	3.4	33
1	What is the potential role of antifibrotic agents for the treatment of liver disease?. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2008 , 5, 496-7		11

